A mini review of Patisiran's efficacy in the management of transthyretin cardiac amyloidosis-Reference-Cited by-同舟云学术

A mini review of Patisiran's efficacy in the management of transthyretin cardiac amyloidosis

Published:2024-09-12 Issue:1 Volume:1 Page:
ISSN:3004-8885
Container-title:Discover Medicine
language:en
Short-container-title:Discov Med

Author:

Olatunji Gbolahan,Kokori Emmanuel,Ogieuhi Ikponmwosa Jude,Ezeano Chimezirim,Omoworare Oluwatobi,Olatunji Doyin,Kanagala Sai Gautham,Elisha Ayilola Ayotomiwa,Aboyeji Deborah,Oluwatobiloba Awoyinfa Michael,Ayodeji Komolafe Babajide,Asieduwaa Owusu Yaa,Uduigwome Emmanuel Obokhai,Yusuf Ismaila Ajayi,Olanisa Olawale,Aderinto Nicholas,Venkatraman Aarushi,Adebayo Yewande Abigail

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s44337-024-00066-y.pdf

Reference22 articles.

1. Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Fail. 2019;6(6):1128–39. https://doi.org/10.1002/ehf2.12518.

2. Smiley DA, Rodriguez CM, Maurer MS. Transthyretin cardiac amyloidosis: an evolution in diagnosis and management of an “old” disease. Cardiol Clin. 2022;40(4):541–58. https://doi.org/10.1016/j.ccl.2022.06.008.

3. Fenoglio R, Baldovino S, Barreca A, Bottasso E, Sciascia S, Sbaiz L, Papotti M, Roccatello D. Renal involvement in transthyretin amyloidosis: the double presentation of transthyretin amyloidosis deposition disease. Nephron. 2022;146(5):481–8. https://doi.org/10.1159/000522370.

4. Spencer-Bonilla G, Alexander KM, Witteles RM. Advances in the diagnosis and management of transthyretin amyloid cardiomyopathy. Curr Treat Options Cardio Med. 2020;22:45. https://doi.org/10.1007/s11936-020-00844-8.

5. Plumadore E, Lombardo L, Cabral KP. Pharmacotherapy review: emerging treatment modalities in transthyretin cardiac amyloidosis. Am J Health-Syst Pharm. 2022;79(2):52–62. https://doi.org/10.1093/ajhp/zxab356.